Ilivia 7 VR-T DX 404624; Intica 7 VR-T DX 404633; Intica 5 VR-T DX 404688; Ilivia 7 VR-T 404625; Intica 7 VR-T 404634; I
Biotronik, Inc. · Decision date Sep 25, 2026
What did the FDA approve?
On 2026-09-25, FDA recorded an approval decision on P050023/S204, a PMA supplement submitted by Biotronik, Inc. under the Normal 180 Day Track. The supplement reason is listed as Change Design/Components/Specifications/Material, and the device category is an implantable dual-chamber defibrillator (product code MRM, Cardiovascular specialty). The title field names Ilivia 7 VR-T DX 404624, Intica 7 VR-T DX 404633, Intica 5 VR-T DX 404688, Ilivia 7 VR-T 404625, Intica 7 VR-T 404634 and further truncated entries.
The recorded statement refers to the next generation of the Home Monitoring Service Center (HMSC), tying the supplement to that monitoring component rather than to a new approval of the entire device system. The source record does not specify which components, specifications or materials changed, what testing supported the change, or how the listed model numbers relate to the HMSC. No documents were included, so the supplement's scope and any conditions of approval remain unknown from this record.
FDA approval order statement
the next generation of the Home Monitoring Service Center (HMSC)
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 25, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P050023/S204
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik, Inc.
- Product code
- MRM
- Decision code
- APPR
- Decision date
- Sep 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: DEFIBRILLATOR, IMPLANTABLE, DUAL-CHAMBER.
- Applicant
- Biotronik, Inc.
- Product code
- MRM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P050023. Subsequent supplements may change the device or its indications.
FDA decision timeline
P050023 · Original PMA
TUPOS LV/ATX & KRONOS LV-T CRT-D & COROX OWT STEROID LV PACING LEAD
P050023/S204 received
Application receipt date recorded by FDA.
P050023/S211 · Related supplement
PSW 2601.U, NEO 2601.U, Acticor Sky HF-T, Rivacor Sky HF-T, Rivacor Rise HF-T, Rivacor Aura HF-T, Acticor Sky HF-T QP, R
P050023/S214 · Related supplement
Acticor Sky HF-T, Rivacor Sky HF-T, Rivacor Rise HF-T, Rivacor Aura HF-T, Acticor Sky HF-T QP, Rivacor Sky HF-T QP, Riva
P050023/S204 · FDA decision
Normal 180 Day Track
P050023/S213 · Related supplement
Acticor Sky HF-T 481986; Rivacor Sky HF-T 481991; Rivacor Rise HF-T 482017; Rivacor Aura HF-T 482013; Acticor Sky HF-T Q
P050023/S215 · Related supplement
Ilivia 7 VR-T DX DF-1 ProMRI Ilivia 7 VR-T DF-1 ProMRI Ilivia 7 VR-T DF4 ProMRI Intica 7 VR-T DX DF-1 ProMRI Intica 7 VR
P050023/S209 · Related supplement
BIOexpress
P050023/S216 · Related supplement
Ilivia 7 VRT DX, Intica 7 VRT DX, Intica 5 VRT DX, Ilivia 7 VRT, Intica 7 VRT, Intica 5 VRT, Inlexa 7 VRT, Inlexa 7 VRT
Timeline entries are records held by MedtechLedger for P050023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P050023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA approval | Aug 10, 2006 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
BIOexpressP050023/S209 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA |
Explore the linked device profile
Other records with product code MRM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
BIOexpressP000009/S128 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P050023/S204
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





